Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GeneIII

Explore full profile

A synthetic biology company integrating ergothioneine research and development,

ChinaFounded 2021Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2025
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for GeneIII and the history behind them.

About GeneIII

Jiangsu Only Three Biotechnology (GeneIII) is a synthetic biology company established in August 2021, with its headquarters in Nanjing, Jiangsu. The company integrates research and development, production, and sales, positioning itself as a key international supplier of ergothioneine raw materials. GeneIII was founded by Chairman Ding Wei, who holds a Master's degree in Materials Engineering from the University of Science and Technology Beijing and another from the University of Nevada, USA. Before establishing GeneIII, Ding Wei had an extensive career, serving as a senior vice president at A.O. Smith Group and president of its China division, as well as CEO of Hengjie Group, accumulating over 20 original patents. The company was co-founded by Chief Scientist Dr. Wang Yang, who holds a Ph.D. in pharmacy from Oregon State University and has postdoctoral experience in biomedical science from UIUC.

Read full description

The company's core business revolves around the production and supply of high-purity ergothioneine, a potent antioxidant used in the health and beauty industries. GeneIII employs synthetic biology techniques to achieve the engineering and mass production of this ingredient, reaching a purity of 99.99%. This production method, which the company likens to a "4x100-meter relay" race encompassing strain construction, fermentation, purification, and scaled-up production, has enabled a significant cost reduction, making ergothioneine more accessible. The business model involves supplying this raw material to various sectors and also developing its own consumer products under brands like "GeneIII" and "HA&EGT 玻麦妍". Their product line includes the high-purity ergothioneine raw material, ergothioneine capsules, and skincare products like serums and lotions. The company operates on a cGMP-compliant manufacturing platform, which allows for a monthly production capacity of up to 3 tons, sufficient to meet global market demands.

Since its inception, GeneIII has achieved notable milestones. Within two years, it successfully scaled the production of ergothioneine, drastically lowering its market price. The company has been recognized for its contributions, selected for CCTV's "Quality China" program and included in the "Industrial Value Gold List of Synthetic Biology" alongside established industry players. This rapid growth and technological achievement have attracted investors such as CITIC Group, HY Capital, and JAFCO Asia. GeneIII's strategy focuses on creating an "anti-aging ecosystem" centered around ergothioneine, exploring new applications, and developing composite formula products. The company aims to be more than just a raw material supplier by building a comprehensive synthetic biology platform. Keywords: Ergothioneine, synthetic biology, antioxidant, raw material supplier, skincare ingredients, nutraceuticals, cGMP manufacturing, fermentation, anti-aging, biotechnology, Ding Wei, Wang Yang, GeneIII, HA&EGT, Nanjing, biomanufacturing, cosmetic ingredients, health supplements, cell protection, industrial-scale production

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
China
Employees
1
Open positions
None listed
Dealroom signal
26.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Synthetic Biology, Spinout, Biotech and Pharma, biomanufacturing, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
b2b

Latest news

Press, funding announcements and product moves mentioning GeneIII.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AEquity / VC Jul 2025 $3.4M $79M TUOXIN · Gaoxin Capital
SEEDEquity / VC Apr 2025 $14M $55M HY Capital · JIF Capital
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

GeneIII website traffic

Latest recorded traffic for GeneIII is 820 monthly website visits, up 28.1% over the last three months.

Latest monthly visits820 3-month web change+28.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • CITIC Group
  • JIF Capital
  • HY Capital

Series A2 investors entered at this stage

  • TUOXIN
  • Gaoxin Capital

Other known investors1 additional known investor

  • Nanjing University of Science and Technology
Employees 1 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇦 Canada100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GeneIII on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GeneIII’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.